Abstract GluN2B subtype-selective NMDA antagonists represent promising therapeutic targets for the symptomatic treatment of multiple CNS pathologies. A series of N-benzyl substituted benzamidines were synthesised and the benzyl ring was further replaced with ...
[Falkiner, Michael J.; Littler, Stuart W.; McRae, Kenneth J.; Savage, G. Paul; Tsanaktsidis, John Organic Process Research and Development, 2013 , vol. 17, # 12 p. 1503 - 1509]